Biotalys NV, a transformative food and crop protection company, announced the appointment of Wim Ottevaere as Chief Financial Officer. Wim joins the Executive Management Team and will be based in Ghent. He will provide strategic financial leadership and will be focused on supporting the organization towards its next financing event.
Wim brings more than 40 years of experience in strategic financial roles, raising close to €1billion for multiple biotech companies across various markets. He successfully brought private companies to public markets in Europe (Euronext) and the U.S.A. (Nasdaq) and has a broad and global network of investors and financial institutions.
In addition to his new role at Biotalys, Wim will continue to act as non-executive director for several biotech companies. Prior to joining Biotalys, until September 2018, he was Chief Financial Officer of Ablynx, a leading Belgian biotech company that was listed on Euronext Brussels and Nasdaq until its acquisition by Sanofi in June 2018 for €3.9 billion. Before that, he was Chief Financial Officer of Innogenetics (now Fujirebio Europe), a biotech company listed on Euronext Brussels at that time. Wim has held various positions in finance and administration prior to joining Innogenetics. Wim holds a Master’s degree in Business Economics from the University of Antwerp, Belgium.
“As we prepare to bring our first biofungicide to market in 2022, Wim Ottevaere completes our executive team and provides the financial expertise Biotalys needs to support our growth. I am looking forward to his strategic input as we build the future of Biotalys to protect crops and food around the globe,” commented Patrice Sellès, CEO of Biotalys.
Wim Ottevaere, CFO of Biotalys, added, “Biotalys has a promising technology platform and a broad product pipeline across the entire crop disease and protection spectrum. Joining Biotalys at this exciting time in its corporate growth journey, I look forward to working with the rest of the executive team to help Biotalys navigate the journey to its next phase as an international commercial player.”
Biotalys